Chemotherapy responsiveness in a patient with multiply relapsed ameloblastic fibro-odontosarcoma of the maxilla

Research output: Contribution to journalArticle

Authors

  • Khin Thway
  • Henry Mandeville
  • Cyrus Kerawala
  • David MacVicar
  • Julia Chisholm

Colleges, School and Institutes

External organisations

  • Paediatric Drug Development, Children and Young People's Unit, The Royal Marsden NHS Foundation Trust, Sutton, UK; and at the Division of Clinical Studies and Cancer Therapeutics, The Institute of Cancer Research, Sutton, UK.
  • Department of Pathology, The Royal Marsden NHS Foundation Trust, Sutton, UK.
  • Department of Radiotherapy, The Royal Marsden NHS Foundation Trust, Sutton, UK.
  • Head and Neck Unit, The Royal Marsden NHS Foundation Trust, Sutton, UK.
  • Department of Radiology, The Royal Marsden NHS Foundation Trust, Sutton, UK.

Abstract

Ameloblastic fibro-odontosarcoma (AFOS) is an extremely rare malignant odontogenic tumor. Complete surgical excision is the treatment of choice. Deaths due to disease recurrence and/or progression are documented. Here, we report the case of a 15-year-old female with multiple recurrent AFOS. She responded to chemotherapy with ifosfamide and doxorubicin consolidated by stereotactic reirradiation using cyberknife and remained in complete remission 14 months from the end of reirradiation therapy. Chemotherapy with ifosfamide and doxorubicin should be considered in advanced cases of AFOS.

Details

Original languageEnglish
Pages (from-to)2029-2032
Number of pages4
JournalPediatric Blood & Cancer
Volume62
Issue number11
Early online date15 Jul 2015
Publication statusPublished - Nov 2015

Keywords

  • Ameloblastoma/surgery, Child, Female, Fibrosarcoma/surgery, Humans, Maxillary Neoplasms/surgery, Neoplasm Recurrence, Local/surgery, Radiosurgery, Remission Induction